GA-TSYS
12.9.2019 14:02:03 CEST | Business Wire | Press release
TSYS (NYSE: TSS) today announced a new authentication product that provides unprecedented real-time verification of customer identities. The new offering, the TSYS Authentication PlatformSM , relies on customer experience data collected from direct cardholder touchpoints and integrates into TSYS clients’ existing authentication systems. TSYS Authentication Platform is available in Europe and will be launched in North America in 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190912005131/en/
The new product is designed to verify that a person is who he or she claims to be, reducing application, transaction and account takeover fraud, while still providing a frictionless customer experience. It’s effective at combatting synthetic identity fraud because it does not rely on reported data, which inherently creates inefficient lag time in the verification process.
The platform utilizes the latest technology – including machine learning – to provide real-time, informed opinions about any type of remote customer interaction or transaction with a financial institution for both consumer and commercial relationships. Examples include originating an account, updating a customer profile, changing a password or making a purchase.
TSYS can provide unparalleled cross-issuer and cross-border insight thanks to its relationships with more than 130 card issuers worldwide.
“At TSYS, we understand how various transactions are connected because we work with a global network of card issuers representing millions of individual accounts,” said Justin Griggs, senior vice president of product strategy and commercialization, TSYS Issuer Solutions. “If a device has been compromised in Ireland, for example, we can use that information to flag a remote login attempt in North America. We have real-time knowledge of potential fraud issues, and now we’re using that information to help our clients authenticate their customers and transactions across any use case.”
The TSYS Authentication Platform aids TSYS customers with their compliance needs to align with the European Union’s Payment Service Directive 2 (PSD2) and Strong Customer Authentication (SCA) provision by providing the ability to flexibly keep pace with the rapidly evolving world of authentication.
TSYS partnered with four key companies to develop the product:
- Featurespace , the leading provider of the award-wining, scalable ARIC™ platform and inventor of Adaptive Behavioral Analytics, previously collaborated with TSYS on the TSYS Foresight Score SM transaction fraud product. The new Authentication Platform utilizes Featurespace’s flexible multi-tenant capabilities that enables an industry-wide view of new fraud vectors for advanced decisioning.
- Emailage is a global leader in online fraud prevention and email risk assessment. Emailage’s technology leverages email address metadata, state of the art machine learning and dynamic data from a global network to generate multi-dimensional identity profiles and render a fraud risk score. This helps users build better informed fraud decision making processes.
- InAuth is a leading digital device intelligence company that specializes in using browser and app information to authenticate online transactions. It will ensure that TSYS clients know and understand the trustworthiness of every device interacting with their digital channels, including mobile app, mobile web and desktop.
- Payfone is the leading digital identity authentication network for the connected world. Their solutions enable consumers and businesses to transact with trust across all channels. Payfone can improve “pass rates” while thwarting synthetic IDs and identity theft with real-time, passive authentication and predictive identity confidence through their proprietary Trust Score™. They will measure the potential risk associated with a digital identity, so users can trust they know who their customers are.
TSYS will continue to enhance its authentication measures to help combat the fraud landscape and expects to leverage additional functionality such as facial recognition, document scanning, and behavioral biometrics, as well as utilize differentiated data sets through 2020 and beyond.
For more information about the TSYS Authentication Platform visit https://www.tsys.com/authentication-platform
About TSYS
TSYS® (NYSE: TSS) is a leading global payments provider, offering seamless, secure and innovative solutions across the payments spectrum — for issuers, merchants and consumers. We succeed because we put people and their needs at the heart of every decision to help them unlock payment opportunities. It’s an approach we call People-Centered Payments® .
Our headquarters are located in Columbus, Ga., U.S.A., with approximately 13,000 team members and local offices across 13 countries. TSYS generated revenue of $4.0 billion in 2018, while processing more than 32.3 billion transactions. We are a member of The Civic 50 and were named one of the 2018 World's Most Ethical Companies by Ethisphere magazine. TSYS is a member of the S&P 500 and routinely posts all important information on its website. For more, visit tsys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005131/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
The Biggest Predictor of Business Growth Is Behavior30.4.2026 09:00:00 CEST | Press release
New IDEO research reveals a gap in the behaviors that most drive growth: long-term vision, rapid experimentation, and team autonomy—with only 10% of leaders saying their company excels at the combination. IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media &
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 00:22:00 CEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 22:30:00 CEST | Press release
Surgeon-Founded Brand Anchored by Innovative NAC Y2™ Technology The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
